Prostacyclin reduction of regional ischemic injury in the canine myocardium.
The effect of prostacyclin (PGI2) on the myocardium of the awake dog subjected to coronary artery occlusion was examined. Animals were randomly administered PGI2 200 ng/kg/min (n = 6), PGI2 100 ng/kg/min (n = 6), or the vehicle control (n = 6), beginning 30 min prior to coronary artery occlusion. Radiolabeled microspheres (15 microns) were used to measure myocardial blood flow. The myocardial region at risk was determined by fluorescein injection, and infarct size was assessed by triphenyl tetrazolium staining. Segmental myocardial function was evaluated from the systolic ejection shortening (SES) by subendocardial ultrasonic dimension crystals in normal, ischemic, and border zones. PGI2 200 ng/kg/min produced significant decreases in aortic pressure and systemic vascular resistance. PGI2 100 ng/kg/min, which achieves 95% platelet inhibition, had no significant hemodynamic effects. Animals receiving PGI2 200 ng/kg/min had significantly higher blood flow to the ischemic region, better border zones SES, and a smaller infarct. PGI2 ameliorates myocardial injury and reduces functional impairment produced by ischemia in doses that elicit vasodilation. This beneficial effect of PGI2 does not appear to be mediated solely by an antiplatelet mechanism.